There’s something exciting about watching your favorite characters excel academically —  maybe because romanticizing studying ...

If you've watched last week's vlog, you'll know that while driving back through Wales we crashed our rickshaw. We left you on a pretty scary cliffhanger - not because it made good TV but because it ...

Week 3 of the NFL schedule features a number of intriguing matchups, including six divisional matchups, such as an AFC West heavyweight matchup between the Denver Broncos vs. Los Angeles Chargers (-3) ...

Investors bid up D-Wave Quantum stock in conjunction with the Federal Reserve's move to cut interest rates this week. D-Wave stock also got a big boost from a competitor's new contract with the Air ...

Looking for a new series to binge? Figuring out Fall TV schedules can be hard, especially with streaming. So, we’re making it easy for you. This week, you’ve got quite a few options for things to ...

We might earn a commission if you make a purchase through one of the links. The McClatchy Commerce Content team, which is independent from our newsroom, oversees this content. This article has ...

The chorus to Radiohead’s 30-year-old classic mod-rock song “Just” applies to the feeling you get when you’ve trusted the Dallas Cowboys to win as a favorite at home for your Survivor “life.” ...

Does Michigan football play this week? Nope, the No. 20 Wolverines will be off for Week 5 with a bye after traveling to Lincoln, Nebraska, for a 30-27 win against the Cornhuskers on Saturday, Sept. 20 ...

The alleged killer of conservative organizer Charlie Kirk is locked up, but top officials of the American government say they are launching a mass pursuit of who really did it. “Terrorists killed ...

Is Alvin Kamara about to feast against the Giants? Will Woody Marks go off on the Ravens? Michael Florio highlights RBs to start and sit in Week 5 of the NFL fantasy season. Should you trust Jaxson ...

BASEL, Switzerland and LONDON and NEW YORK and DURHAM, N.C., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced positive results from the Phase 3 VALOR ...

Once-daily oral brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all nine key secondary endpoints, ...